Psychiatry · Medical Literature
Adjunctive fecal microbiota transplantation for major depressive disorder: A randomized, double-blind, placebo-controlled trial.
Abstract
Gut microbiota may influence antidepressant treatment outcomes, yet whether targeted modulation can enhance efficacy remains unclear. We conducted a randomized, double-blind, placebo-controlled trial in patients with major depressive disorder, administering a 2-week course of fecal microbiota transplantation (FMT) capsules or placebo as an adjunct to escitalopram (ChiCTR2300071421). Remission rates at week 8 did not differ significantly between groups, but FMT produced greater reductions in Hamilton Depression Rating Scale, 17-item version (HAMD-17) scores at weeks 2 and 8. FMT was well-tolerated with a safety profile comparable to placebo. Multi-omics analyses show durable donor microbial engraftment and enrichment of beneficial Lachnospiraceae and Oscillospiraceae taxa. Microbial remodeling is accompanied by an increase in serum bile acids that correlate with the alleviation of depressive symptoms. Mediation analysis supports a bile-acid-mediated suppression of inflammatory pathways linking microbial changes to antidepressant effects. Overall, FMT may provide a safe avenue to enhance escitalopram efficacy through microbiota-directed regulation of bile-acid metabolism and inflammation.
Clinical relevance
Does a 2-week adjunctive course of oral fecal microbiota transplantation (FMT) capsules improve remission rates and depressive symptom severity compared to placebo when added to escitalopram in adults with major depressive disorder? __SNAPSHOT__ {"studyDesign":"Randomized, double-blind, placebo-controlled trial (ChiCTR2300071421)","setting":"Beijing Anding Hospital, Capital Medical University, Beijing, China; single academic psychiatric center","sampleSize":"n=60 randomized (FMT: n=30, placebo: n=30); 56 completed the 8-week study (93.3% retention)","population":"Adults with major depressive disorder (MDD); mean age 29.6 years (range 19.7–60.7); 63.3% female; 40% first-episode MDD; all initiated on escitalopram prior to randomization","intervention":"Oral FMT capsules administered over 2 weeks as adjunct to escitalopram (5–20 mg/day, dose range per tolerability)","comparator":"Matched oral placebo capsules over 2 weeks, with concurrent escitalopram at equivalent doses","primaryOutcome":"Remission rate at week 8, defined as HAMD-17 total score ≤ 7","followUp":"8 weeks (primary endpoint); multi-omics biological sampling at weeks 2 and 8","fundingSource":"Not reported in abstract; institutional affiliations include Capital Medical University and Chongqing Medical University (government-affiliated academic institutions); no industry sponsor identified in available text"}
Key findings
PRIMARY OUTCOME (NOT MET): The remission rate at week 8 (HAMD-17 ≤ 7) was 43.3% in the FMT group vs. 26.7% in the placebo group, an absolute difference of 16.7 percentage points (95% CI, −9.4 to 40.1; p = 0.1760), which did not reach statistical significance. The NNT for remission at week 8 is approximately 6 (calculated: 1/0.167), but this estimate is clinically uninformative given the non-significant primary endpoint. SECONDARY OUTCOMES: The early response rate at week 2 (HAMD-17 reduction ≥ 50%) was significantly higher in the FMT group (30.0%) versus placebo (6.7%), an absolute difference of 23.3 percentage points (95% CI, 1.1–43.7; p = 0.0195). FMT also produced significantly greater reductions in continuous HAMD-17 total scores at both weeks 2 and 8 compared to placebo, and the HAMD-17 anxiety/somatic subscale score differed significantly between groups (95% CI, −5.5 to −0.3; p = 0.0303). No significant between-group differences were observed in GAD-7 or Gastrointestinal Symptom Rating Scale (GSRS) scores. MECHANISTIC FINDINGS: Multi-omics analyses demonstrated durable donor microbial engraftment, with enrichment of Lachnospiraceae and Oscillospiraceae taxa. Three serum bile acids—glycocholic acid (GCA, p = 0.011), glycodeoxycholic acid (GDCA, p = 0.033), and taurochenodeoxycholic acid (TCDCA, p = 0.04)—showed significantly greater increases at week 2 in the FMT group. Mediation analysis identified IL-22RA1 changes at week 2 as a partial mediator of FMT's beneficial effect on depressive symptoms (ACME = 0.93; 95% CI, 0.11–2.18; p = 0.012). SAFETY: Adverse events were reported in 30.0% of the FMT group vs. 26.7% of placebo (no statistically significant difference); the most common AEs were nausea and fatigue. Two serious adverse events (one attempted suicide, one myocardial infarction) occurred, both in the placebo group, and both were adjudicated as unrelated to the study intervention. Blinding integrity was confirmed (correct guess rate 32% FMT vs. 44.8% placebo, non-significant). Note: p-values for secondary HAMD-17 continuous score comparisons at individual time points were not fully enumerated in the available abstract; not all secondary p-values reported here are extractable from the abstract alone.
Practice implications
This trial established that adjunctive oral FMT capsules did not significantly improve remission rates (the pre-specified primary endpoint) at 8 weeks in adults with MDD receiving escitalopram. The trial was likely underpowered to detect the observed 16.7 percentage-point remission difference, as a sample size of n=60 provides insufficient power to reliably detect a moderate treatment effect with this outcome rate variability. Statistically significant early symptomatic benefit was observed on continuous HAMD-17 scores and the week-2 response rate, but these are secondary endpoints and must be interpreted with caution given the failed primary outcome and the absence of correction for multiple comparisons. The mechanistic data linking FMT-induced microbial engraftment → bile acid elevation → anti-inflammatory signaling → symptom improvement is hypothesis-generating and biologically plausible, but mediation analyses from small samples cannot establish causality. Findings apply specifically to adults with MDD who are concurrently initiating or receiving escitalopram; patients with treatment-resistant depression, those on alternative antidepressants, pediatric or geriatric populations, and non-Han Chinese populations were not adequately represented. The short 8-week follow-up precludes conclusions about durability of any symptomatic benefit. NOTE: Only the published abstract and publicly accessible portions of the full text were used to generate this summary; readers should consult the full paper for complete statistical reporting, supplementary tables (S4–S10), and power calculation details. __LIMITATIONS__ Small sample size (n=60 total; n=30 per arm): almost certainly underpowered to detect the observed primary endpoint difference, making the non-significant primary result uninterpretable as true equivalence.,Short follow-up (8 weeks): insufficient to assess durability of symptomatic effects or long-term safety of microbiome remodeling.,Single-center design at one Chinese academic psychiatric institution severely limits generalizability across ethnic, dietary, and healthcare system contexts.,Young, predominantly female, relatively non-treatment-resistant population (mean age ~30, 40% first-episode): results may not generalize to older adults, males, or patients with prior antidepressant failures.,All patients received escitalopram concurrently; the independent antidepressant effect of FMT, and its generalizability to other antidepressant backbones, cannot be assessed.,Secondary endpoints (continuous HAMD-17 scores, response rates) were not adjusted for multiplicity, inflating Type I error risk for secondary findings.,Mediation analyses (bile acid pathway, IL-22RA1) are exploratory and cannot establish causality from observational biomarker data within a small RCT.,Funding source not explicitly reported in available text; institutional conflicts of interest cannot be fully assessed.,HAMD-17, while validated, is a clinician-rated scale subject to assessor bias; blinding success was confirmed but assessor independence is not detailed.,The 2-week FMT administration window may be insufficient to produce durable microbiome reconstitution; optimal dosing regimen remains undefined. __BOTTOM_LINE_CATEGORY__ promising_but_preliminary __BOTTOM_LINE__ This small (n=60), single-center RCT found that adjunctive oral FMT capsules did not significantly improve the primary endpoint of 8-week remission rates in MDD patients receiving escitalopram, though secondary measures suggested earlier and greater symptomatic reductions in HAMD-17 scores in the FMT group. The trial was almost certainly underpowered to detect a clinically meaningful primary endpoint difference, and the mechanistic bile-acid/anti-inflammatory pathway findings are hypothesis-generating only. FMT for MDD should not enter routine clinical practice on the basis of this study; adequately powered, multicenter replication trials with longer follow-up are needed before clinical translation can be considered.